Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice

INTRODUCTION: Low blood-brain barrier (BBB) penetration and hematopoietic side effects limit the therapeutic development of erythropoietin (EPO) for Alzheimer's disease (AD). A fusion protein of EPO and a chimeric monoclonal antibody targeting the mouse transferrin receptor (cTfRMAb) has been e...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jiahong, Yang, Joshua, Whitman, Kathrine, Zhu, Charlene, Cribbs, David H., Boado, Ruben J., Pardridge, William M., Sumbria, Rachita K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6807369/
https://www.ncbi.nlm.nih.gov/pubmed/31660425
http://dx.doi.org/10.1016/j.trci.2019.09.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6807369/
https://www.ncbi.nlm.nih.gov/pubmed/31660425
http://dx.doi.org/10.1016/j.trci.2019.09.003

Ejemplares similares